Page 43 - 2018_09-Mondo

HHT for the hematologist
intestinal bleeding. Gut. 2004;53(4):609-
612.
70. Lebrin F, Srun S, Raymond K, et al.
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16(4):420-428.
71. Gordon M, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothe- lial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843-850.
72. Dupuis-Girod S, Ambrun A, Decullier E, et al. ELLIPSE Study: a Phase 1 study evaluat- ing the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hered- itary hemorrhagic telangiectasia. Mabs. 2014;6(3):794-799.
73. Kim YH, Kim MJ, Choe SW, Sprecher D, Lee Y, P Oh S. Selective effects of oral antiangio- genic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiec-
tasia. J Thromb Haemost. 2017;15(6):1095-
1102.
74. Ruiz S, Chandakkar P, Zhao H, et al.
Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology. Hum Mol Genet. 2017;26(24): 4786-4798.
75. Samour M, Saygin, C., Abdallah, R., Kundu, S., McCrae, K.R. Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study. Blood. 2016;128(22):210.
76. Warkentin TE, Moore JC, Morgan DG. Gastrointestinal angiodysplasia and aortic stenosis. N Engl J Med. 2002;347(11):858- 859.
77. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;360(20):2143-2144.
78. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic
telangiectasia. N Engl J Med. 2009;361(9):
931; author reply 931-932.
79. Brinkerhoff BT, Poetker DM, Choong NW.
Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2011;364(7):688-689.
80. Thompson AB, Ross DA, Berard P, Figueroa- Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol (Providence). 2014;5(2):91-95.
81. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiec- tasia associated with bleeding. Am J Hematol. 2016;91(6):E313-314.
82. Guilhem A, Fargeton AE, Simon AC, et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retro- spective study of 46 patients. PLoS One. 2017;12(11):e0188943.
haematologica | 2018; 103(9)
1443